Island Pharmaceuticals (ASX:ILA) Receipts from Customers: A$0.00 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ILA Island Pharmaceuticals Ltd ASX:ILA
27 GF Score
Price A$0.42
! 1 Warning Sign
View Full Analysis

What is Island Pharmaceuticals Receipts from Customers?

Island Pharmaceuticals ASX:ILA +6.41% 27 Receipts from Customers is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:ILA with a GF Score™ of 27/100. The stock has 1 warning sign investors should review.

Island Pharmaceuticals's Receipts from Customers for the six months ended in Dec. 2025 was A$0.00 Mil.

Island Pharmaceuticals's Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Island Pharmaceuticals Receipts from Customers Historical Data

* Premium members only.

The historical data trend for Island Pharmaceuticals's Receipts from Customers can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Island Pharmaceuticals Receipts from Customers Chart

Island Pharmaceuticals Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Receipts from Customers
0.00 0.00 0.00 0.00 0.00

Island Pharmaceuticals Semi-Annual Data
Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Receipts from Customers Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ILA
27GF Score
Island Pharmaceuticals Ltd ASX:ILA
Receipts from Customers is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Island Pharmaceuticals Receipts from Customers Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Receipts from Customers represents payment received from customers in the direct cash flow method.

Receipts from Customers for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Receipts from Customers of A$0.00 Mil mean?
Island Pharmaceuticals (ASX:ILA) has a Receipts from Customers of A$0.00 Mil as of Dec. 2025. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Island Pharmaceuticals and its competitors.
Is Island Pharmaceuticals' Receipts from Customers too high?
Island Pharmaceuticals' current Receipts from Customers is A$0.00 Mil. Overall, Island Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Island Pharmaceuticals' Receipts from Customers compare to VRTX and REGN?
Island Pharmaceuticals' Receipts from Customers of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receipts from Customers for a Biotechnology company?
A good Receipts from Customers depends on the Biotechnology industry context. However, Receipts from Customers should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receipts from Customers mean?
A high Receipts from Customers can signal that a stock is expensive relative to its fundamentals. Receipts from Customers represents payment received from customers in the direct cash flow method. View historical data for Island Pharmaceuticals and its competitors. Island Pharmaceuticals's current Receipts from Customers is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Island Pharmaceuticals stock overvalued right now?
Island Pharmaceuticals (ASX:ILA) has a current Receipts from Customers of A$0.00 Mil. The current Receipts from Customers is A$0.00 Mil. Island Pharmaceuticals' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receipts from Customers calculated?
Receipts from Customers is calculated from a company's financial statements. For Island Pharmaceuticals (ASX:ILA), the current Receipts from Customers is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Island Pharmaceuticals Business Description

Address c/- Bio101 Financial Advisory Pty Ltd, 697 Burke Road, Suite 201, Camberwell, Melbourne, VIC, AUS, 3124
Island Pharmaceuticals Ltd is a drug research and repurposing company focused on developing preventative or therapeutic drugs for viral infections, public health, or biosecurity threats. The company is following a dual development plan for its assets, ISLA-101 and Galidesivir. Its product candidate, ISLA-101, is being repurposed for the prevention and treatment of dengue fever and other mosquito-borne (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika, and Yellow fever viruses, with unmet medical needs. The company operates in a single segment, being research and development activities in Australia and the United States of America.
27GF Score

Get the complete analysis for ASX:ILA

Receipts from Customers is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price